Low-dose warfarin therapy leading to embryopathy: a case report
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20253923Keywords:
Anticoagulants, Fetal warfarin syndrome, Warfarin, EmbryopathyAbstract
The development of specific dysmorphic features known as warfarin embryopathy or fetal warfarin syndrome is more likely to occur in fetuses exposed to maternal consumption of warfarin. Nasal hypoplasia and stippling of the vertebrae or bony epiphysis are the most consistent characteristics. Anticoagulation in pregnant patients might be difficult to manage. According to current recommendations, heparin or low-dose warfarin (≤5 mg/day) should be used. We report the case of a pregnancy where the mother was anticoagulated with low-dose warfarin due to a mechanical mitral valve. Warfarin was required at a dose of 3 and 4 mg on alternate days and was switched to heparin from 10+4 weeks to 12 weeks. Nevertheless, the fetus presented with the signs of warfarin embryopathy. Through this report, we emphasize the need for optimising the choice and dosage of anticoagulants during pregnancy so as to provide the best maternal and fetal outcome.
Metrics
References
Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med. 1980;68(1):122-40. DOI: https://doi.org/10.1016/0002-9343(80)90181-3
Stevenson RE, Burton OM, Ferlauto GJ, Taylor HA. Hazards of oral anticoagulants during pregnancy. JAMA. 1980;243(15):1549-51. DOI: https://doi.org/10.1001/jama.1980.03300410037022
Hou JW. Fetal warfarin syndrome. Chang Gung Med J. 2004;27(9):691-5.
Wainwright H, Beighton P. Warfarin embryopathy: fetal manifestations. Virchows Arch. 2010;457(6):735-9. DOI: https://doi.org/10.1007/s00428-010-0982-9
Steinberg ZL, Dominguez-Islas CP, Otto CM, Stout KK, Krieger EV. Maternal and Fetal Outcomes of Anticoagulation in Pregnant Women With Mechanical Heart Valves. J Am College Cardiol. 2017;69(22):2681-91. DOI: https://doi.org/10.1016/j.jacc.2017.03.605
Canobbio MM, Warnes CA, Aboulhosn J, Connolly HM, Khanna A, Koos BJ et al. Management of Pregnancy in Patients With Complex Congenital Heart Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2017;135(8):e50-87. DOI: https://doi.org/10.1161/CIR.0000000000000458
Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000;160(2):191-6. DOI: https://doi.org/10.1001/archinte.160.2.191
European Society of Gynecology (ESG); Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine (DGesGM); Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(24):3147-97. DOI: https://doi.org/10.1093/eurheartj/ehr218
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(23):2440-92. DOI: https://doi.org/10.1161/CIR.0000000000000029
Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999;33(6):1637-41. DOI: https://doi.org/10.1016/S0735-1097(99)00044-3
D’Souza R, Ostro J, Shah PS, Silversides CK, Malinowski A, Murphy KE, et al. Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis. Eur Heart J. 2017;38(19):1509-16. DOI: https://doi.org/10.1093/eurheartj/ehx032
Franco B, Meroni G, Parenti G, Levilliers J, Bernard L, Gebbia M, et al. A cluster of sulfatase genes on Xp22.3: mutations in chondrodysplasia punctata (CDPX) and implications for warfarin embryopathy. Cell. 1995;81(1):15-25. DOI: https://doi.org/10.1016/0092-8674(95)90367-4
Khamoushi AJ, Kashfi F, Hosseini S, Alizadeh Ghavidel AR, Samiei N, Haddadzadeh M. Anti-coagulation during pregnancy in women with mechanical heart valves: a prospective study. Int J Fertil Steril. 2011;5(1):47-51.
Hassouna A, Allam H. Limited dose warfarin throughout pregnancy in patients with mechanical heart valve prosthesis: a meta-analysis. Interact Cardiovasc Thorac Surg. 2014;18(6):797-806. DOI: https://doi.org/10.1093/icvts/ivu009
Cotrufo M, De Feo M, De Santo LS, Romano G, Della Corte A, Renzulli A, et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol. 2002;99(1):35-40. DOI: https://doi.org/10.1097/00006250-200201000-00008
Mazibuko B, Ramnarain H, Moodley J. An audit of pregnant women with prosthetic heart valves at a tertiary hospital in South Africa: a five-year experience. Cardiovasc J Afr. 2012;23(4):216-21. DOI: https://doi.org/10.5830/CVJA-2012-022
Basu S, Aggarwal P, Kakani N, Kumar A. Low-dose maternal warfarin intake resulting in fetal warfarin syndrome: In search for a safe anticoagulant regimen during pregnancy. Birth Defects Res A Clin Mol Teratol. 2016;106(2):142-7. DOI: https://doi.org/10.1002/bdra.23435
Khan AO. Optic nerve dysfunction in a child following low-dose maternal warfarin exposure. Ophthalmic Genet. 2007;28(3):183-4. DOI: https://doi.org/10.1080/13816810701537408
Finkelstein Y, Chitayat D, Schechter T, Keating S, Toi A, Koren G. Motherisk rounds. Warfarin embryopathy following low-dose maternal exposure. J Obstet Gynaecol Can. 2005;27(7):702-6. DOI: https://doi.org/10.1016/S1701-2163(16)30550-3
Downloads
Published
How to Cite
Issue
Section
